A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 28; no. 15_suppl; p. 3008
Main Authors	Di Cosimo, S., Bendell, J. C., Cervantes-Ruiperez, A., Roda, D., Prudkin, L., Stein, M. N., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., Baselga, J.
Format	Journal Article
Language	English
Published	20.05.2010
Online Access	Get full text

Loading…